A Randomized, Double-blind, Multi-center, Standard Therapy Based, Placebo parallel Controlled Phase II Clinical Trial to Evaluate the Effect of Recombinant Human Neuregulin-1 for Injection on the Survival

Trial Profile

A Randomized, Double-blind, Multi-center, Standard Therapy Based, Placebo parallel Controlled Phase II Clinical Trial to Evaluate the Effect of Recombinant Human Neuregulin-1 for Injection on the Survival

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Recombinant human neuregulin 1-beta (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 23 May 2013 Results published in a Zensun Sci & Tech media release.
    • 21 May 2012 Planned end date (18 Dec 2011) added as reported by Chinese Clinical Trial Register.
    • 05 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top